Gilead Sciences (FRA:GIS) Tariff Resilience Score: 8/10 (As of Jul. 11, 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €114.96
GF Value €85.09
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Tariff Resilience Score?

Gilead Sciences FRA:GIS -1.52% 75 Tariff Resilience Score is 8 as of Jul. 11, 2026. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €85.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Gilead Sciences ranks better than 99.61% on this metric.

Gilead Sciences has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Gilead Sciences has Gilead Sciences has a global supply chain but benefits from pharmaceutical industry exemptions. Its diverse market presence and pricing power provide resilience against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Gilead Sciences might have Highly Resilient.

Gilead Sciences  (FRA:GIS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Gilead Sciences Tariff Resilience Score Related Terms

FRA:GIS vs PFE, AMGN, BMY: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Tariff Resilience Score falls into.


FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Gilead Sciences (FRA:GIS) has a Tariff Resilience Score of 8 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Gilead Sciences ranks #4 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Gilead Sciences' Tariff Resilience Score too high?
Gilead Sciences' current Tariff Resilience Score is 8. Based on the distribution chart, Gilead Sciences ranks #4 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Tariff Resilience Score compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #4 out of 1029 companies for Tariff Resilience Score. This places Gilead Sciences in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Gilead Sciences's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €85.09, compared to a current price of €114.96 — trading 35.1% above its estimated fair value. The current Tariff Resilience Score is 8. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Tariff Resilience Score is 8 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €114.96 is trading 35.1% above its estimated GF Value™ of €85.09. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Tariff Resilience Score: 8
  • GF Value™: €85.09 vs. price of €114.96 (35.1% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€114.96
Price
€85.09
GF Value